PKN605-AF

A randomized, placebo-controlled, participant- and investigator-blinded study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of oral PKN605 in participants with atrial fibrillation

Stage: inclusie
Medicine: PKN605
Population: Ritme
Phase: II
First Patient In: 15 December 2025
Last Patient In: 15 November 2026
Last Patient Last Visit: 15 August 2027

Inclusion period, 310 days remaining

Study Director

dr. M.E.W. Hemels

Cardioloog

Office Contact

M.J. van Doorn

WCN